More on ATOS
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $2.49 |
|
|||
| Open | $2.46 | ||||
| 52 Wk High | $3.64 | ||||
| 52 Wk Low | $0.14 | ||||
| Day High | $2.60 | ||||
| Day Low | $2.39 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 106,083 | ||||
- Atossa Therapeutics Announces Presentation of Mechanism-Driven (Z)-Endoxifen Data in McCune-Albright Syndrome at AACR Special Conference on Rare Cancers
- Rodman & Renshaw Starts Atossa Genetics (ATOS) at Buy
- Atossa Therapeutics closes $4.5 million registered direct offering
- Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds
- Form 424B5 ATOSSA THERAPEUTICS,
- Atossa Therapeutics raises $4.5 million in registered direct offering
- Form 8-K ATOSSA THERAPEUTICS, For: Jun 10
- Atossa Therapeutics Announces Registered Direct Offering of up to $16.5 Million in Gross Proceeds
- Atossa presents preclinical data on breast cancer drug at ASCO 2026
- Atossa Therapeutics Announces ASCO 2026 Abstracts Highlighting (Z)-Endoxifen Activity Across ESR1 Mutations and Ongoing EVANGELINE Phase 2 Trial
Entities mentioned with ATOS
- FDA | View Related Stories »
- Earnings | View Related Stories »
- Definitive Agreement | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Maxim Group | View Related Stories »
- 13G | View Related Stories »
- Show More...
